BiotechTube
Immunologik

Immunologik

Hamburg, Germany· Est.
immunologik.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ImmunoLogik is a private, preclinical-stage biotech developing host-targeted antivirals for HIV and coronaviruses. Its lead candidates, IML-106 for HIV and IML-206 for SARS-CoV-2/other coronaviruses, aim to block essential cellular pathways used by viruses for replication, potentially reducing the risk of drug resistance. The company leverages strong academic ties, notably with the University Hospital Erlangen, and is supported by the strategic and operational expertise of the Athenion Group. It is currently pre-revenue and focused on advancing its pipeline through preclinical development.

Infectious DiseaseImmunology

Technology Platform

Host-targeted antiviral platform focusing on inhibiting specific cellular structures in humans that are essential for viral replication, aiming to reduce the risk of drug resistance.

Opportunities

Significant unmet need in treating multi-drug resistant HIV and the ongoing threat of coronavirus pandemics creates large addressable markets.
A successful host-targeted, broad-spectrum antiviral could be a key asset for global pandemic preparedness portfolios.

Risk Factors

High preclinical development risk, including potential toxicity from targeting host pathways.
Intense competition in both HIV and COVID-19 therapeutic spaces from large pharma.
Uncertain commercial market for COVID-19 drugs post-pandemic.

Competitive Landscape

In HIV, competes against established antiretroviral regimens and newer therapies from giants like Gilead and ViiV. In coronaviruses, faces competition from direct-acting antivirals (e.g., Paxlovid) and numerous other host-targeted approaches in development globally.

More companies in Immunotherapy / Immuno-Oncology →More companies in Germany →